Filociclovir - Microbiotix
Alternative Names: CPV; Cyclopropavir; MBX-400; NSC-D745998; ZSM-I-62Latest Information Update: 28 Sep 2024
At a glance
- Originator Wayne State University School of Medicine
- Developer Microbiotix
- Class Antivirals; Cyclopropanes; Hypoxanthines; Purinones; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors; Ganciclovir kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Adenovirus infections; Cytomegalovirus infections
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Adenovirus-infections in USA
- 28 Jul 2023 No recent reports of development identified for phase-I development in Cytomegalovirus infections(In volunteers) in USA (PO, Capsule)
- 25 Aug 2020 Filociclovir is still in phase I trials for Cytomegalovirus infections in the US (Microbiotix pipeline August 2020)